Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers
Tachyon Therapeutics, a private, clinical-stage biotechnology company developing transformative cancer therapies against novel targets today […]
BRIM Biotechnology Announces First Patient Enrollment in Pivotal Phase 3 Clinical Trial of BRM421 for Dry Eye Disease
BRIM Biotechnology, a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure […]
Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome
Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam […]
Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping & Ablation Catheter
Galvanize Therapeutics today announced the first human investigational use of its large-area, focal, Pulsed Electric […]
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
Atom Bioscience, a clinical-stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced […]
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
Maze Therapeutics, a company translating genetic insights into new precision medicines, has announced positive results […]
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Nektar Therapeutics today announced topline data from a Phase 2 randomized, double-blind, placebo-controlled study of […]
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
Forge Biologics, a genetic medicines development and manufacturing organization, announced today that Maria Escolar, M.D., […]
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes
Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer […]
Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects
Mezzion Pharma has submitted a confirmatory pivotal Phase 3 Clinical Trial in Fontan subjects to […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more